Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

Their aim was to investigate the effect of semaglutide on cognitive function in PWH and the possible mediation of this effect by changes in adiposity or inflammation.

Why It Was Studied

People with human immunodeficiency virus (HIV, PWH) are at higher risk for visceral adiposity, enhanced inflammation, and cognitive decline than controls who do not have HIV.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Some participants received a placebo instead of Semaglutide, giving a reference point.

In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo.

The primary outcome was the change in cognitive function at 32 weeks.

Secondary measures included changes in body composition and inflammatory markers.

Causal mediation analysis assessed semaglutide's direct and indirect effects on Cognivue scores through changes in adiposity and inflammation.

What Was Measured

The subject headings attached to it are HIV Infections, Cognition, Glucagon-Like Peptides, Inflammation and Adiposity.

Author keywords: Cognivue, PWH, cognitive function, glucagon-like peptide-1 receptor agonist and people with HIV.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America), a journal based in United States.

More context: the Semaglutide compound page, all human trials.